Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 38.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,033 shares of the biopharmaceutical company's stock after selling 5,705 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in Halozyme Therapeutics were worth $432,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares during the last quarter. LPL Financial LLC lifted its position in Halozyme Therapeutics by 36.6% in the fourth quarter. LPL Financial LLC now owns 207,003 shares of the biopharmaceutical company's stock valued at $9,897,000 after buying an additional 55,410 shares during the last quarter. Samalin Investment Counsel LLC boosted its stake in Halozyme Therapeutics by 8.8% during the fourth quarter. Samalin Investment Counsel LLC now owns 10,607 shares of the biopharmaceutical company's stock worth $507,000 after buying an additional 860 shares during the period. Fox Run Management L.L.C. purchased a new position in Halozyme Therapeutics during the fourth quarter worth about $489,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at about $1,253,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $64.02 on Tuesday. The company has a market cap of $7.91 billion, a P/E ratio of 18.66, a PEG ratio of 0.42 and a beta of 1.32. The firm has a fifty day moving average price of $58.39 and a 200 day moving average price of $54.68. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $66.00.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, Benchmark reissued a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.